Author: Dr Daniel Mazzoni, Junior Medical Officer, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia. DermNet NZ Editor-in-Chief: Adjunct A/Prof. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. January 2019.
Legius syndrome is a rare genetic disorder first described in 2007 . It is also known as neurofibromatosis type 1-like syndrome .
Legius syndrome is classically characterised by multiple light brown macules, known as café-au-lait macules . Unlike neurofibromatosis type 1, there are no tumours in Legius syndrome.
Legius syndrome may occur in anyone with at least one biological parent with genetically confirmed Legius syndrome . The prevalence of Legius syndrome is unknown, but may be higher than expected due to misdiagnosis as neurofibromatosis type 1 .
Legius syndrome is a genetic condition inherited in an autosomal dominant manner that involves a SPRED1 gene mutation on chromosome 15q14. This results in the abnormal function of the SPRED1 protein, which is responsible for regulating specific cell signalling pathways involved in cell proliferation, differentiation and apoptosis. No other pathogenic variants have been found to cause Legius syndrome [2,3].
As an autosomal dominant condition, Legius syndrome may occur in anyone with at least one biological parent who has genetically confirmed Legius syndrome. Rarely, it may occur de novo, but these cases have not been evaluated sufficiently to confirm this . Each child that has a parent with genetically confirmed Legius syndrome has a 50% risk of inheritance.
The clinical features of Legius syndrome vary significantly in nature and severity from one person to another.
Almost all patients with Legius syndrome present with multiple café-au-lait macules [2,3]. The number of these macules tends to increase during childhood .
Other common cutaneous features may include:
Non-cutaneous features may include:
Neuropsychiatric features may include:
The intellectual disabilities are generally less severe in patients with Legius syndrome compared to those with neurofibromatosis type 1 .
Importantly, Legius syndrome does not cause neurofibromas and Lisch nodules, which are typically seen in neurofibromatosis type 1 [2,3].
Legius syndrome is difficult to diagnose on a clinical basis alone given the similar cutaneous clinical presentation to other disorders with multiple café-du-lait macules.
Where Legius syndrome is suspected, genetic testing can be used to confirm the diagnosis. This involves:
Suspicious findings that may warrant genetic testing include:
Legius syndrome is often misdiagnosed because the pigmentary manifestations are very similar to other syndromes with multiple lentigines. Correct diagnosis is critical to guide long-term monitoring and management.
Other syndromes characterised by multiple lentigines include:
Children with Legius syndrome should be under regular screening and evaluation for developmental delay, cognitive impairment, and behavioural issues .
Treatment of Legius syndrome is primarily supportive and should be focused on the specific problems of the affected individual.
Appropriate management if indicated may include:
Patients with Legius syndrome have a generally good prognosis with appropriate problem-based management.
An affected individual must consider the 50% risk of genetic transmission to each child.
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.